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Background: Radical antegrade modular pancreatosplenectomy (RAMPS) is a relatively new modification of the
standard distal pancreatosplenectomy. In this method, dissection proceeds from right-to-left to achieve negative
posterior resection margins. However, short-term and long-term outcomes of RAMPS for pancreatic cancer have
not yet been clarified. The aim of this study is to evaluate short-term and long-term outcomes in the patients who
have undergone RAMPS.
Methods: Consecutive 49 patients were selected from the retrospective database of the Kanagawa Cancer Center
from 2000 to 2014. Data from the operative notes, pathology reports, postoperative data, and outpatient data
(recurrence and survival) were entered into the database.
Results: All patients were undergone anterior RAMPS. The median operation time was 278 min (range from
140 to 625 mins). The median blood loss in operation was 850 ml (range from 60 to 2790 ml). The overall
incidence of morbidity was 51.4 % and the incidence of mortality was 0 %. Forty-one patients (83.7 %) had
negative resection margins. The mean number of lymph nodes harvested was 15 and 27 patients had lymph
node metastasis. After the median follow-up period was 41.1 months, 1-year and 3-year overall survival rates
were 84.1 and 38.6 %, respectively. Median overall survival was 22.6 months.
Conclusions: The present study results suggested that RAMPS procedure might be safe and feasible without
an increase in morbidity and morbidity and have survival benefit compared with standard DP.
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Pancreatic cancer, with a five-year survival rate of 5–10 %,
is the fourth leading cause of cancer-related death in de-
veloped countries [1]. Complete resection is essential for
cure. Distal pancreatectomy (DP) has been the standard
procedure for the resection of tumors of the body and tail
of the pancreas for over 100 years [2].* Correspondence: t-aoyama@lilac.plala.or.jp
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(http://creativecommons.org/publicdomain/zeAdenocarcinoma of the pancreatic body and tail are
as aggressive as pancreatic head tumors in terms of
local invasion and their propensity for lymph node
metastasis. To achieve a cure, it is therefore essential
to perform a complete resection of the tumor with a
margin of normal tissue and to resect the regional
lymph nodes. However, the traditional approach of
left-to-right pancreatosplenectomy is associated with a
high rate of tangential margin positivity [3, 4], and is
not based on the lymphatic drainage of the organ.
Strasberg et al. [2, 3] described an operative technique
that allows for a more complete dissection of posterioricle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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the resection of all of the regional nodes. Radical ante-
grade modular pancreatosplenectomy (RAMPS) is a
relatively new modification of the standard distal pan-
creatosplenectomy procedure. In this method, dissection
proceeds from right-to-left in 1 of 2 posterior dissection
planes to achieve negative posterior resection margins.
The accompanying N1 lymph node dissection is based
on the established anatomy of lymph node drainage of
this part of the pancreas. Recently, some literatures had
been published about surgical outcomes of the RAMPS
[5, 6], however, outcomes of RAMPS in the treatment of
pancreatic cancer remain to be clarified.
The aim of the present study is to evaluate the
short-term and long-term outcomes of 49 patients
who underwent RAMPS and to compare the results
with the results of previously published surgical case
series in which open and laparoscopic procedures
were performed in patients with adenocarcinoma of
the pancreatic body and tail.Methods
Patients
The patients were selected from the retrospective
database of the Kanagawa Cancer Center from 2000
to 2014. The patients were selected according to the
following criteria: (1) a histologically proven pancre-
atic adenocarcinoma located in the body and tail of
pancreas according to the seventh edition of the
International Union Against Cancer (UICC) TNM [7];
(2) the patients underwent distal pancreatosplenect-
omy as the primary treatment for pancreatic adeno-
carcinoma; (3) the patients underwent surgery that
consisted of dissection of more than the N1 lymph
nodes and which achieved a curative or R1 resection;
(4) the patients did not have synchronous or meta-
chronous malignancies. Patients with pancreatic cancer
derived from intraductal papillary mucinous neoplasms,
mucinous cystic neoplasms, and neuroendocrine tumors
were excluded from the present study.Procedure
We performed the RAMPS procedure in patients with
adenocarcinoma of the pancreatic body and tail. The ini-
tial dissection in the RAMPS procedure begins medially.
The splenic artery and vein are ligated and the neck of
the pancreas is transected. The dissection continues pos-
teriorly to the aorta at the celiac and superior mesenteric
trunks. The resection plane is decided based on the pro-
gression of cancer. In patients in whom the tumor ap-
pears to penetrate the adrenal gland (or more deeply),
the plane of dissection is deepened to the posterior plane
behind the adrenal gland.Perioperative care
In principle, all of the patients received the same peri-
operative care. In brief, the patients were allowed to eat
until midnight on the day before the surgery and were
required to drink the contents of two 500-ml plastic bot-
tles containing oral rehydration solution until 3 h before
surgery. The nasogastric tube was removed on postoper-
ative day 1 after surgery. Oral intake was initiated on
POD 2, beginning with water and an oral nutritional
supplement. The patients began to eat solid food on
POD 5 (starting with rice gruel and soft food on POD 3
and advancing in three steps to regular food intake on
POD 7). The patients were discharged when they had
achieved adequate pain relief and soft food intake, had
returned to their preoperative level of mobility and ex-
hibited normal laboratory data.
Adjuvant chemotherapy
Based on the results of CONKO-001 [8], the patients
received gemcitabine adjuvant treatment from 2007 to
2011. Treatment with gemcitabine was initiated within
eight weeks after surgery. The patients received a
weekly dose of 1,000 mg/m2 for three weeks, followed
by one week of rest. S-1 chemotherapy was started
within 10 weeks after surgery. Based on the results of
JASPAC-01, the patients received S-1 adjuvant treat-
ment from 2011 to 2014 [9]. The patients received S-1
(40 mg/m2 of body-surface area) twice a day for four
weeks, followed by two weeks of rest as one course
(six-week schedule) or two weeks followed by one week
of rest as one course (three-week schedule). In principle,
all patients continued gemcitabine or S-1 treatment for
six months.
Follow up
The patients were followed up at outpatient clinics. The
levels of the CEA and CA19-9 tumor markers were mea-
sured at least every three months for five years. All pa-
tients underwent CT examinations every three months
during the first three years after surgery; CT examina-
tions were then performed every six months until five
years after surgery.
Evaluations and statistical analysis
Overall survival was calculated from the date of first sur-
gery to the date of death by any cause or the last day of
follow-up. The two groups were compared by unpaired
Student’s t-test or the Χ2 test. P values of <0.05 were
considered to be statistically significant. The data are
presented as medians ± ranges. Survival curves were cal-
culated using the Kaplan-Meier method and compared
using the log-rank test. This study was approved by the
Institutional Review Board of Kanagawa Cancer Center
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pliance with the Declaration of Helsinki.Results
The background of the patients
Forty-nine patients were eligible for inclusion in the
present study. The median patient age was 68 years
(range: 46-86 years). Thirty-one patients were male,
and 16 were female. The median follow-up period
was 41.1 months (range: 5.6-98.3 months). Forty-six
patients received adjuvant chemotherapy after surgery
(gemcitabine adjuvant chemotherapy [n = 23], gemcita-
bine plus S-1 adjuvant chemotherapy [n = 1], and S-1
adjuvant chemotherapy [n = 22]. Three patients re-
fused to undergo adjuvant chemotherapy.Surgical findings and complications
All of the patients underwent anterior RAMPS. The me-
dian operation time was 278 min (range: 140–625 min).
The median operative blood loss was 850 ml (range:
60–2790 ml). Blood transfusion was required in 11 of
49 patients (22.4 %). Postoperative complications oc-
curred in 20 patients (40.8 %). Table 1 showed the
operative findings and surgical complications. The
surgical complications were graded according to the
Clavien-Dindo classification system [10, 11]: grade 2
complications occurred in 18 patients (36.7 %), a
grade 3a complication occurred in one patient (2.1 %),
and a grade 3b occurred in one patient (2.1 %). The mean
hospital stay was 21 days (range: 8–57 days).Table 1 Operative findings and surgical complications
Operative findings
Operation time (min) 257 (140–625)
Estimated blood loss 610 (60–2790)
Transfusion (%) 6 (15.3 %)
Length of hospital stay (day) 21 (8–57)
Surgical complications
Clavien-Dindo Grade II Pancreatic fistula 14 (28.6 %)
Delayed gastric empty 3 (6.1 %)
Surgical site infection 1 (2.1 %)
Clavien-Dindo Grade IIIa Intraabdominal abscess 1 (2.1 %)
Clavien-Dindo Grade IIIb Intraabdominal abscess 1 (2.1 %)




DPM positive 7/39 (17.9 %)Pathological findings
Three patients had T1 tumors, 1 patient had a T2 tumor,
37 patients had T3 tumors and 4 patients had T4 tu-
mors. Twenty-seven of the 49 patients had positive
lymph nodes (55 %). According to American Joint Com-
mittee on Cancer Staging of Tumors, 3 patients had
Stage IA disease, 15 patients had Stage IIA, 23 patients
had Stage IIB, and 8 patients had Stage III. The tumors
ranged from 5–83 mm in diameter (mean diameter;
38 mm). Thirteen patients had well-differentiated tu-
mors, 22 patients had moderately differentiated tumors,
8 patients had poorly differentiated tumors, 2 patients
had anaplastic carcinoma, 2 patients had papillary
adenocarcinoma, and 1 patient had mucinous and ade-
nosquamous carcinoma. The mean number of lymph
nodes harvested was 15, 27 patients had lymph node
metastasis. Forty-one patients (83.7 %) had negative re-
section margins.
Overall survival and recurrence free survival
At the time of writing, 25 of the 49 patients (51 %) are
alive and 24 patients (49 %) have died. Nineteen of the
25 surviving patients (38.8 %) showed no evidence of re-
currence, while 6 (12.2 %) patients are alive with recur-
rence. The median overall survival was 22.6 months.
The 1-year and 3-year overall survival rates were 84.1
and 38.6 %, respectively (Fig. 1). Thirty of 49 patients ex-
perienced recurrence. The sites of recurrence included
the liver (n = 6), the lymph nodes (n = 11), the pancreatic
bed (n = 6), the peritoneum (n = 5), and the lungs (n = 1).
Among 11 lymph nodes recurrences patients, 8 patients
recurred in para-aortic lymph node, 3 patients recurred
in para-superior mesenteric artery lymph node.
Discussion
We evaluated the short-term and long-term results of
the RAMPS procedure for pancreatic cancer. The overall
incidence of morbidity was 51.4 %, while the incidence
of mortality was 0 %. Moreover, median survival was
22.6 months and 5-year overall survival was 27 %. These
results suggest the safety and feasibility of the RAMPS
procedure and indicate the possibility that it could be
performed without an increase in morbidity or mortality
and that it might offer a survival benefit in comparison
to standard DP.
Although postoperative complications occurred in 20
of the 49 patients (40.8 %), there were no postoperative
or in-hospital deaths. Pancreatic fistula was the most fre-
quently diagnosed complication, followed by abdominal
abscess. The overall incidence of morbidity and mortal-
ity were similar to other RAMPS studies. Mitchem et al.
[12] evaluated the long-term results of RAMPS among
47 patients who underwent anteroposterior RAMPS.
They found that the overall in-hospital mortality rate
Fig. 1 Cumulative survival rates after Radical antegrade modular pancreatosplenectomy (RAMPS) for adenocarcinoma of the pancreatic body and tail
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patients). In addition, Chang et al. [13] evaluated the
surgical outcome of RAMPS in 24 consecutive pa-
tients. They demonstrated that the overall in-hospital
mortality rate was 0 % and that the morbidity rate
was 37.5 % (9 patients). Previous studies have shown
the incidence of the morbidity after conventional dis-
tal pancreatomy to be 23–58 % [14, 15]. These find-
ings suggest the safety and feasibility of the RAMPS
procedure and indicated that it is not associated with
increased morbidity or mortality.
After the median follow-up period was 41.1 months, 1-
year and 3-year overall survival rates were 84.1 and 38.6 %,
respectively. Median overall survival was 22.6 months.
Similar results were observed in the previous RAMPS
studies. Table 2 showed the comparison of other published






Brennan (1996) [4] 4 Standard 34 23 % 0 %
Mitchem (2012) [12] 15 RAMPS 47 39 % 0 %
Chang (2012) [13] 16 RAMPS 24 37.5 % 0 %
Latorre (2013) [17] 20 RAMPS 8 25 % 0 %
Trottman (2014) [16] 19 RAMPS 6 50 % 0 %
Kitagawa (2014) [5] 5 RAMPS 24 58 % 0 %
Park (2014) [6] 6 Standard 54 22.2 % 0 %
RAMPS 38 18.4 % 0 %
Our study (2015) – RAMPS 49 41 % 0 %Mitchem et al. reported a median survival period of
26 months and a 5-year overall survival rate of 35 % in
47 patients who underwent anteroposterior RAMPS. In
the same study, they reported that 23 patients who
underwent RAMPS more than 5 years before the date
of last follow-up, had a 5-year survival rate of 30.4 %.
RAMPS appeared to offer superior survival in compari-
son to standard DP at high volume centers; the previ-
ously reported 5-year survival rates have ranged from
10–19 %. The first possible reason is that the negative
margin rate was higher in the RAMPS procedures than
in standard DP. When comparing with previous re-
ports, the negative margin rate was 80–90 % in the pre-
vious RAMPS studies, while the negative margin was
70–80 % in the standard DP studies (Table 2). A second
possibility is that different numbers of lymph nodes







13 68 % 12 14 %
18.0 91.0 % 26 36 %
20.9 91.7 % 18.2 NA
20.7 87.5 % 14 26 %
11.2 100 % NA NA
24 88 % NA 53 %
9 85.1 % NA 12.0 %
14 89.5 % NA 40.1 %
15 83.7 % 22.6 27 %
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which RAMPS and standard resection was performed
to identify differences in the clinicopathological out-
comes of the patients. They demonstrated a significant
difference in the mean number of lymph nodes that
were removed in standard resection (4.3) and RAMPS
(11.2) (P = 0.03). Moreover, La Torre et al. [17] com-
pared the clinicopathological outcomes of 25 patients
who underwent RAMPS or standard resection. They
too demonstrated a significant difference in the mean
number of lymph nodes that were removed in standard
resection (16.2) and RAMPS (20.7) (P = 0.04).
The RAMPS procedure should be tested against stand-
ard DP in a randomized trial. According to Mitchem
et al., a prospective randomized, controlled study should
be performed to better determine the long-term out-
comes. They calculated that in order to compare the two
treatments with 5-year survival rates of 20 and 35 %, a
total of 556 patients (228 patients per group) would be
required to detect a difference at the 95 % CI. Such
numbers would be difficult to obtain in a single institu-
tion because resections of adenocarcinoma of the pan-
creatic body and tail are uncommon in comparison to
resections of the pancreatic head.
Special attention is required when interpreting the
current results, because several potential limitations are
associated with the present study. First, the present
study was a retrospective analysis which was performed
in a single institution. We cannot deny the possibility
that our findings were observed by chance. Second,
there was a selection bias in the patients in this series.
Surgeons often avoid performing pancreatomy in the
some patients, because pancreatectomy itself has a 1–
1.5 % mortality rate and a 40–60 % morbidity rate.
Thus, the fact that some of the patients in the present
study received pancreatectomy could, in and of itself,
be a potential bias. In addition, our hospital is a special-
ized cancer center. The third issue is the follow-up
period. In our series, the median follow-up period was
approximately 36 months. Our follow-up period may
not have been sufficient to allow definite conclusions to
be drawn. Considering these limitations, the current re-
sults should be validated in other series with a larger
number of patients.Conclusions
The results indicate that the RAMPS procedure might
be safe feasible for the treatment of pancreatic cancer
and that it might offer a survival benefit in comparison
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